- About
- Dean’s Office
- Research
- Education
- Patient Care
- People
- News
- Events
B. Joseph Guglielmo, PharmD
Dean
Troy C. Daniels Distinguished Professor of Pharmaceutical Sciences
Associate Vice Chancellor, Pharmacy Affairs
Phone: +1 415 476-8010
Fax: +1 415 502-3612
513 Parnassus Ave, MSB, Rm 128
UCSF Box 0403
San Francisco, CA 94117
United States Links
Educational programs
MD Degree Program
UCSF centers, institutes, and research programs
Antimicrobial Stewardship Program, UCSF Medical Center
Infectious Diseases Consult Service, UCSF Medical Center
Chancellor’s Executive Council and Committees
Board of Directors, Clinical and Translational Science Institute (CTSI)
What I do
As dean of the UCSF School of Pharmacy, I lead the creation of the School’s strategic agenda and ensure the School has the operational framework and resources required to succeed in its mission. My work is in collaboration with the School’s department chairs, administrative leaders, and faculty. On the campus level, I join UCSF’s chancellor and other campus leaders to ensure UCSF continues its leadership in innovative health sciences research, patient care, and the graduate education of tomorrow’s scientists and clinicians. I am also a pharmacist who cares for patients, a clinical scientist, teacher, and mentor. My professional focus is on the evidence–based use of antimicrobials to treat infections.
Departmental research area
My research expertise
personalized medicine/pharmacogenomics, evidence-based health care, epidemiology/pharmacoepidemiology, health economics and pharmacoeconomics, global health, medication safety, pharmacy practice, pharmacokinetics/pharmacodynamics
Clinical expertise
evidence-based pharmacotherapy, infectious diseases
Degrees
PharmD, University of Southern California (USC), 1978
BS, Biology, Santa Clara University, 1973
Biography
B. Joseph Guglielmo, PharmD, is a pharmacist, clinical scientist, teacher, and international expert in the evidence-based use of antimicrobials to treat infections.
He was named dean of the UCSF School of Pharmacy in 2012 and holds the Troy C. Daniels Distinguished Professorship in Pharmaceutical Science.
As dean, Guglielmo oversees the activities and progress of three departments; a campus organized research unit; and a dean’s office charged with School administration and finance, strategic planning, communications, academic affairs, and the development and delivery of a doctor of pharmacy (PharmD) degree program. His leadership as dean actively supports the distinguishing UCSF concept of One UCSF and upholds the institution’s PRIDE values.
During his tenure as dean, the School of Pharmacy has remained the top recipient among pharmacy schools nationwide of research dollars from the National Institutes of Health (NIH), and its PharmD degree program has remained among the top-rated such programs in the nation.
Guglielmo initiated a transformation of the PharmD degree program, which welcomed its first class in 2018. The program’s foundation of scientific thinking evolves from the distinctive scientific mindset of the faculty, and the faculty’s drive to seek and apply new knowledge across research, education, and patient care.
Guglielmo is widely known as an advocate for therapeutics-related research, from basic science to health policy research. As chair of the School's Department of Clinical Pharmacy, Guglielmo oversaw a 40 percent increase in the Department of Clinical Pharmacy’s faculty research funding. He created the department-run Medication Outcomes Center in 2007 to improve medication use at UCSF Health and beyond. In the late 1980s he developed the UCSF Medical Center Antimicrobial Stewardship Program to ensure the safe, effective use of antimicrobials, focusing upon decreasing antimicrobial resistance. The program was one of the earliest programs of its kind in the United States.
As patients seek new and cost-effective health care with increasingly complicated disease states and medications, Guglielmo advocates for research on new ways for pharmacists to care for patients, especially in the community. He also supports strong relationships among clinical scientists and their upstream basic and translational scientist colleagues, as demonstrated through his own collaborations. Guglielmo has been actively involved in the UCSF Clinical and Translational Science Institute (CTSI) from its inception and during its renewal; he has also served as past associate director of the CTSI Mentor Development Program.
His personal research agenda involves the safe, effective, and appropriate use of antimicrobials, as well as the pharmacoepidemiology and pharmacokinetics of anti-infective agents. He is the author of numerous peer-reviewed papers, book chapters, and abstracts, the majority related to anti-infective agents.
He believes that the most important clinical research is shaped through the researcher’s own clinical experiences. Together with his administrative, research, and teaching responsibilities, he continues to be active as an infectious diseases pharmacist supporting the UCSF Medical Center Antimicrobial Stewardship Program and serving on the Infectious Diseases Consult Service team. These experiences continue to provide the background for important hypothesis-centered research on the safe, effective use of antimicrobials.
Beyond the hospital, Guglielmo developed clinical pharmacy services for UCSF HIV/AIDS programs, specifically for the HIV Women's Program and the Men of Color Program.
Guglielmo has taught doctor of pharmacy students, pharmacy residents and fellows, medical students and residents, and infectious diseases fellows for decades, and he has mentored infectious diseases specialty pharmacist residents and fellows continuously since 1986. He has also mentored a number of international scholars, including Fogarty fellows.
He is the recipient of many teaching awards, including the UCSF Lifetime Achievement in Mentoring Award, Resident Preceptor of the Year Awards, UCSF School of Pharmacy Long Teaching Awards, and UCSF Academic Senate Distinction in Teaching Award. He is a fellow of the American College Clinical Pharmacy and the Infectious Diseases Society of America.
Guglielmo earned a PharmD from the University of Southern California in 1978 and completed a PharmD residency at UCSF in 1979.
Research keywords
Medication Errors, Pharmacy Service, Hospital, Medication Reconciliation, Community-Acquired Infections, Community Pharmacy Services, Home Care Services, Metronidazole, Drug Utilization, Vancomycin Resistance, vancomycin, Drug Labeling, Drug-Related Side Effects and Adverse Reactions, Anti-Bacterial Agents, Amphotericin B, Hospital Medication Systems
Licensure and certifications
Licentiate in Pharmacy, California, 1978
Pages
| 1. | Fellow, Infectious Diseases Society America, 2013 |
| 2. | Troy C. Daniels Distinguished Professorship in Pharmaceutical Science, UCSF, 2013 |
| 3. | Fellow, American College of Clinical Pharmacy, 2011 |
| 4. | Faculty Mentoring Program Lifetime Achievement in Mentoring Award, UCSF, 2010 |
| 5. | Vincent G. Pons Award in Clinical Infectious Diseases, UCSF, 2005 |
| 6. | Long Prize for Excellence in Teaching, UCSF, 1999 |
| 7. | Pharmacy Leadership Society Recognition, Phi Lambda Sigma, 1995 |
| 8. | Pharmacy Residents Preceptorship Award, UCSF, 1995 |
| 9. | Fellow, California Society of Health-System Pharmacists, 1993 |
| 10. | Academic Senate Distinction in Teaching Award, UCSF, 1992 |
| 11. | Commencement Speaker, School of Pharmacy, UCSF, 1992 |
| 12. | Pharmacy Residents Preceptorship Award, UCSF, 1989 |
| 13. | Pharmacy Residents Preceptorship Award, UCSF, 1988 |
| 14. | Pharmacy Residents Preceptorship Award, UCSF, 1987 |
| 15. | Long Foundation Award for Excellence in Teaching, UCSF, 1986 |
| 16. | Pharmacy Residents Preceptorship Award, UCSF, 1985 |
| 17. | Long Foundation Award for Excellence in Teaching, UCSF, 1981 |
| 18. | Pharmacy Residents Preceptorship Award, UCSF, 1981 |
Publications
| Guglielmo BJ. Metronidazole Neurotoxicity: Suspicions Confirmed. Clin Infect Dis. 2021 06 15; 72(12):2101-2102. |
| Guglielmo BJ. The Colchicine Debacle Revisited. JAMA Intern Med. 2021 Feb 01; 181(2):287-288. |
| Guglielmo BJ. The Cost of Pharmaceutical Company Detailing Visits and Medication Samples. JAMA Intern Med. 2020 04 01; 180(4):595-596. |
| Meyer-Massetti C, Hofstetter V, Hedinger-Grogg B, Meier CR, Guglielmo BJ. Medication-related problems during transfer from hospital to home care: baseline data from Switzerland. Int J Clin Pharm. 2018 Dec; 40(6):1614-1620. |
| Meyer-Massetti C, Meier CR, Guglielmo BJ. The scope of drug-related problems in the home care setting. Int J Clin Pharm. 2018 Apr; 40(2):325-334. |
| Woldu H, Guglielmo BJ. Incidence and risk factors for vancomycin nephrotoxicity in acutely ill pediatric patients. J Pharm Technol. 2018; 34:9-16. |
| Roy SL, Atkins JT, Gennuso R, Kofos D, Sriram RR, Dorlo TP, Hayes T, Qvarnstrom Y, Kucerova Z, Guglielmo BJ, Visvesvara GS. Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain. Parasitol Res. 2015 Dec; 114(12):4431-9. |
| Cheng CM, Shin J, Guglielmo BJ. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012. JAMA Intern Med. 2014 Oct; 174(10):1704-5. |
| Hardmeier A, Tsourounis C, Moore M, Abbott WE, Guglielmo BJ. Pediatric medication administration errors and workflow following implementation of a bar code medication administration system. J Healthc Qual. 2014 Jul-Aug; 36(4):54-61; quiz 61-3. |
| Gahbauer AM, Gonzales ML, Guglielmo BJ. Patterns of antibacterial use and impact of age, race/ethnicity, and geographic region on antibacterial use in an outpatient medicaid cohort. Pharmacotherapy. 2014 Jul; 34(7):677-85. |
| Tan M, Lau J, Guglielmo BJ. Ethanol locks in the prevention and treatment of catheter-related bloodstream infections. Ann Pharmacother. 2014 May; 48(5):607-15. |
| Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J. 2013 Oct; 32(10):1077-9. |
| Frymoyer A, Lee S, Bonifacio SL, Meng L, Lucas SS, Guglielmo BJ, Sun Y, Verotta D. Every 36-h gentamicin dosing in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. J Perinatol. 2013 Oct; 33(10):778-82. |
| Gwaza L, Aweeka F, Greenblatt R, Lizak P, Huang L, Guglielmo BJ. Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir. Int J Infect Dis. 2013 Oct; 17(10):e857-61. |
| Frymoyer A, Meng L, Bonifacio SL, Verotta D, Guglielmo BJ. Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia. Pharmacotherapy. 2013 Jul; 33(7):718-26. |
| Burrell C, Tsourounis C, Quan D, Bcps , Jue V, Tam E, Guglielmo BJ. Impact of a pharmacist-driven protocol to improve drug allergy documentation at a university hospital. Hosp Pharm. 2013 Apr; 48(4):302-7. |
| Guglielmo BJ. The colchicine debacle. JAMA Intern Med. 2013 Feb 11; 173(3):184-5. |
| Cocohoba JM, Murphy P, Pietrandoni G, Guglielmo BJ. Improved antiretroviral refill adherence in HIV-focused community pharmacies. J Am Pharm Assoc (2003). 2012 Sep-Oct; 52(5):e67-73. |
| Murphy P, Cocohoba J, Tang A, Pietrandoni G, Hou J, Guglielmo BJ. Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy. AIDS Patient Care STDS. 2012 Sep; 26(9):526-31. |
| Swartling M, Gupta R, Dudas V, Guglielmo BJ. Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring. Int J Clin Pharm. 2012 Apr; 34(2):282-5. |
| Cheng CM, Fu C, Guglielmo BJ, Auerbach AD. Boxed warning inconsistencies between drug information resources and the prescribing information. Am J Health Syst Pharm. 2011 Sep 01; 68(17):1626-31. |
| Frymoyer A, Guglielmo BJ, Wilson SD, Scarpace SB, Benet LZ, Hersh AL. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy. 2011 Sep; 31(9):871-6. |
| Guglielmo BJ, Edwards DJ, Franks AS, Naughton CA, Schonder KS, Stamm PL, Thornton P, Popovich NG. A critical appraisal of and recommendations for faculty development. Am J Pharm Educ. 2011 Aug 10; 75(6):122. |
| Meyer-Massetti C, Vaerini S, Rätz Bravo AE, Meier CR, Guglielmo BJ. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Int J Clin Pharm. 2011 Oct; 33(5):806-14. |
| Cheng C, Guglielmo BJ. Invited commentary--prescription drug label adverse events: a call for prioritization: comment on "A quantitative analysis of adverse events and 'overwarning' in drug labeling". Arch Intern Med. 2011 May 23; 171(10):946-7. |
| Meyer-Massetti C, Cheng CM, Schwappach DL, Paulsen L, Ide B, Meier CR, Guglielmo BJ. Systematic review of medication safety assessment methods. Am J Health Syst Pharm. 2011 Feb 01; 68(3):227-40. |
| Macdougall C, Udkow T, Guglielmo BJ, Vittinghoff E, Martin J. National estimates and predictors of prescription medication sample use in the United States, 1999-2005. J Am Pharm Assoc (2003). 2010 Nov-Dec; 50(6):677-85. |
| Sohn AH, Schwartz JM, Yang KY, Jarvis WR, Guglielmo BJ, Weintrub PS. Risk factors and risk adjustment for surgical site infections in pediatric cardiothoracic surgery patients. Am J Infect Control. 2010 Nov; 38(9):706-10. |
| Guglielmo BJ. A prescription for improved chronic disease management: have community pharmacists function at the top of their training: comment on "Engaging physicians and pharmacists in providing smoking cessation counseling". Arch Intern Med. 2010 Oct 11; 170(18):1646-7. |
| Cheng CM, Guglielmo BJ, Maselli J, Auerbach AD. Coverage of FDA medication boxed warnings in commonly used drug information resources. Arch Intern Med. 2010 May 10; 170(9):831-3. |
| Nakamura K, Schwartz BS, Lindegårdh N, Keh C, Guglielmo BJ. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. Clin Infect Dis. 2010 Apr 01; 50(7):e47-9. |
| Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010 Apr; 5(4):E8-16. |
| Koplowicz YB, Schwartz BS, Guglielmo BJ. Development of daptomycin-susceptible, methicillin-resistant Staphylococcus aureus pneumonia during high-dose daptomycin therapy. Clin Infect Dis. 2009 Oct 15; 49(8):1286-7. |
| Martin T, Sharma M, Damon L, Kaplan L, Guglielmo BJ, Working M, O'Malley R, Hwang J, Linker C. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2010 Feb; 12(1):45-50. |
| Feldman MD, Huang L, Guglielmo BJ, Jordan R, Kahn J, Creasman JM, Wiener-Kronish JP, Lee KA, Tehrani A, Yaffe K, Brown JS. Training the next generation of research mentors: the University of California, San Francisco, Clinical & Translational Science Institute Mentor Development Program. Clin Transl Sci. 2009 Jun; 2(3):216-21. |
| Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009 May; 28(5):398-402. |
| Yang K, Zhuo H, Guglielmo BJ, Wiener-Kronish J. Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. Ann Pharmacother. 2009 Jan; 43(1):28-35. |
| Marquez C, Guglielmo BJ, Klausner JD. Five years later: re-examining the financial burden of boosting with Norvir. AIDS. 2008 Nov 12; 22(17):2402-4. |
| Patel D, Lawson W, Guglielmo BJ. Antimicrobial stewardship programs: interventions and associated outcomes. Expert Rev Anti Infect Ther. 2008 Apr; 6(2):209-22. |
| Frenzel T, Lee CZ, Kim H, Quinnine NJ, Hashimoto T, Lawton MT, Guglielmo BJ, McCulloch CE, Young WL. Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance. Cerebrovasc Dis. 2008; 25(1-2):157-63. |
| Schwartz BS, Ngo PD, Guglielmo BJ. Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding? Ann Pharmacother. 2008 Feb; 42(2):289-90. |
| Robinson CA, Cocohoba J, MacDougall C, John MD, Guglielmo BJ. Discordance between ambulatory care clinic and community pharmacy medication databases for HIV-positive patients. J Am Pharm Assoc (2003). 2007 Sep-Oct; 47(5):613-5. |
| Yang K, Guglielmo BJ. Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms. Ann Pharmacother. 2007 Sep; 41(9):1427-35. |
| Riedel A, Choe L, Inciardi J, Yuen C, Martin T, Guglielmo BJ. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. BMC Infect Dis. 2007 Jul 02; 7:70. |
| Nicandro JP, Tsourounis C, Frassetto L, Guglielmo BJ. In vivo effect of I'm-Yunity on hepatic cytochrome P450 3A4. J Herb Pharmacother. 2007; 7(1):39-56. |
| Huang Y, Okochi H, May BC, Legname G, Prusiner SB, Benet LZ, Guglielmo BJ, Lin ET. Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos. 2006 Jul; 34(7):1136-44. |
| Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol. 2006 Mar-Apr; 53(2):121-6. |
| Deck DH, Guglielmo BJ. Pharmacological advances in the treatment of invasive candidiasis. Expert Rev Anti Infect Ther. 2006 Feb; 4(1):137-49. |
| Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ, Lin E, Yang GY, Young WL. Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab. 2006 Sep; 26(9):1157-64. |
| Mendez MN, Gibbs L, Jacobs RA, McCulloch CE, Winston L, Guglielmo BJ. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacotherapy. 2006 Jan; 26(1):61-7. |
| Guglielmo BJ, Dudas V, Maewal I, Young R, Hilts A, Villmann M, Gibbs L, Gropper M, Jacobs R. Impact of a series of interventions in vancomycin prescribing on use and prevalence of vancomycin-resistant enterococci. Jt Comm J Qual Patient Saf. 2005 Aug; 31(8):469-75. |
| MacDougall C, Guglielmo BJ, Maselli J, Gonzales R. Antimicrobial drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis. 2005 Mar; 11(3):380-4. |
| Chang NN, Murray CK, Houck PM, Bratzler DW, Greenway C, Guglielmo BJ. Blood culture and susceptibility results and allergy history do not influence fluoroquinolone use in the treatment of community-acquired pneumonia. Pharmacotherapy. 2005 Jan; 25(1):59-66. |
| Yung L, Huang Y, Lessard P, Legname G, Lin ET, Baldwin M, Prusiner SB, Ryou C, Guglielmo BJ. Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infect Dis. 2004 Nov 29; 4:53. |
| Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. 2004 Jul-Aug; 38(7-8):1148-52. |
| MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother. 2004 Jun; 53(6):899-901. |
| Bower AN, Tang HM, Guglielmo BJ. Compliance in two medical centers with criteria for use of caspofungin and lipid-based amphotericin B. Am J Health Syst Pharm. 2004 May 01; 61(9):915-20. |
| Oren E, Shaffer ER, Guglielmo BJ. Impact of emerging technologies on medication errors and adverse drug events. Am J Health Syst Pharm. 2003 Jul 15; 60(14):1447-58. |
| Phan DD, Chin-Hong P, Lin ET, Anderle P, Sadee W, Guglielmo BJ. Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. Antimicrob Agents Chemother. 2003 Jul; 47(7):2351-3. |
| Hickman DE, Stebbins MR, Hanak JR, Guglielmo BJ. Pharmacy-based intervention to reduce antibiotic use for acute bronchitis. Ann Pharmacother. 2003 Feb; 37(2):187-91. |
| Oren E, Griffiths LP, Guglielmo BJ. Characteristics of antimicrobial overrides associated with automated dispensing machines. Am J Health Syst Pharm. 2002 Aug 01; 59(15):1445-8. |
| Yang K, Guglielmo BJ. Patient education for H pylori: who benefits? West J Med. 2002 Mar; 176(2):97. |
| Graff LR, Franklin KK, Witt L, Cohen N, Jacobs RA, Tompkins L, Guglielmo BJ. Antimicrobial therapy of gram-negative bacteremia at two university-affiliated medical centers. Am J Med. 2002 Feb 15; 112(3):204-11. |
| Botwin KJ, Chan J, Jacobs R, Guglielmo BJ. Restricted access to automated dispensing machines for surgical antimicrobial prophylaxis. Am J Health Syst Pharm. 2001 May 01; 58(9):797-9. |
| Burkiewicz JS, Kostiuk KA, Jacobs RA, Guglielmo BJ. Impact of an intravenous fluconazole restriction policy on patient outcomes. Ann Pharmacother. 2001 Jan; 35(1):9-13. |
| Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother. 2000 Apr; 34(4):446-52. |
| Guglielmo BJ, Luber AD, Paletta D, Jacobs RA. Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis. 2000 Jan; 30(1):205-7. |
| Guglielmo BJ, Luber AD, Corelli RL, Flaherty JF, Jacobs RA. Prevention of adverse events in hospitalized patients using an antimicrobial review program. West J Med. 1999 Sep; 171(3):159-62. |
| Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother. 1999 Feb; 43(2):267-71. |
| Guglielmo BJ. Use of antimicrobial agents in patients with cardiovascular disease. J Cardiovasc Nurs. 1999 Jan; 13(2):23-30. |
| Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998 Sep; 27(3):603-18. |
| Guglielmo BJ, Kostiuk KA, Pons VG. Pharmacokinetics and pharmacodynamics of ceftizoxime in abscess fluid. J Antimicrob Chemother. 1997 Mar; 39(3):437-8. |
| Hashimoto S, Wolfe E, Guglielmo B, Shanks R, Sundelof J, Pittet JF, Thomas E, Wiener-Kronish J. Aerosolization of imipenem/cilastatin prevents pseudomonas-induced acute lung injury. J Antimicrob Chemother. 1996 Nov; 38(5):809-18. |
| Barlows TG, Luber AD, Jacobs RA, Guglielmo BJ. Hypothermia following the intravenous administration of amphotericin B. Clin Infect Dis. 1996 Nov; 23(5):1187-8. |
| Tsourounis C, Guglielmo BJ. Aerosolized amphotericin B in prophylaxis of pulmonary aspergillosis. Ann Pharmacother. 1996 Oct; 30(10):1175-6. |
| Guglielmo BJ, Jacobs RA. Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin. Am J Health Syst Pharm. 1996 Sep 01; 53(17):2097-8. |
| Guglielmo BJ, Quan LA, Stulbarg MS. Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients. J Antimicrob Chemother. 1996 May; 37(5):1040-2. |
| Luber AD, Jacobs RA, Jordan M, Guglielmo BJ. Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococci. J Infect Dis. 1996 May; 173(5):1292-4. |
| Guglielmo BJ. Practical strategies for the appropriate use of antimicrobials. Pharm World Sci. 1995 Jul 28; 17(4):96-102. |
| Wong-Beringer A, Corelli RL, Schrock TR, Guglielmo BJ. Influence of timing of antibiotic administration on tissue concentrations during surgery. Am J Surg. 1995 Apr; 169(4):379-81. |
| Singh RF, Corelli RL, Guglielmo BJ. Sterility of unit dose syringes of filgrastim and sargramostim. Am J Hosp Pharm. 1994 Nov 15; 51(22):2811-2. |
| Kostiuk KA, Pons VG, Guglielmo BJ. Penetration of fluconazole into abscess fluid. J Antimicrob Chemother. 1994 Oct; 34(4):603-5. |
| Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant. 1994 May; 13(5):499-510. |
| Joe LA, Jacobs RA, Guglielmo BJ. Systemic absorption of oral fluconazole after gastrointestinal resection. J Antimicrob Chemother. 1994 May; 33(5):1070. |
| Kanatani MS, Guglielmo BJ. The new macrolides. Azithromycin and clarithromycin. West J Med. 1994 Jan; 160(1):31-7. |
| Wong-Beringer A, Jacobs RA, Guglielmo BJ. Nosocomial funguria: resultant morbidity and therapeutic intervention. Clin Infect Dis. 1993 Dec; 17(6):1066-7. |
| Pons VG, Denlinger SL, Guglielmo BJ, Octavio J, Flaherty J, Derish PA, Wilson CB. Ceftizoxime versus vancomycin and gentamicin in neurosurgical prophylaxis: a randomized, prospective, blinded clinical study. Neurosurgery. 1993 Sep; 33(3):416-22; discussion 422-3. |
| Pons VG, Denlinger SL, Guglielmo BJ, Octavio J, Flaherty J, Derish PA, Wilson CB. Comment; ceftizoxime versus vancomycin and gentamicin in neurosurgical prophylaxis. Neurosurgery. 1993 Sep; 33(3):537. |
| Colford JM, Corelli RL, Ganz JW, Guglielmo BJ, Jacobs RA. Home antibiotic therapy for streptococcal endocarditis: a call for a controlled trial. Am J Med. 1993 Jan; 94(1):111-2. |
| Wong-Beringer A, Jacobs RA, Guglielmo BJ. Treatment of funguria. JAMA. 1992 May 27; 267(20):2780-5. |
| Barriere SL, Guglielmo BJ. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Clin Pharm. 1992 Mar; 11(3):223-35. |
| Corelli RL, Guglielmo BJ, Kapusnik-Uner JE, McMaster JR, Greenblatt RM. Medication usage patterns in patients with human immunodeficiency virus infection: a comparison of patient-reported medication usage with medical chart review. DICP. 1991 Dec; 25(12):1374-8. |
| Glick PL, Guglielmo BJ, Winter ME, Finkbeiner W, Turley K. Iodine toxicity secondary to continuous povidone-iodine mediastinal irrigation in dogs. J Surg Res. 1990 Nov; 49(5):428-34. |
| Glick M, Guglielmo BJ. Antibiotic prophylaxis in cesarean section. DICP. 1990 Sep; 24(9):841-6. |
| Hebert MF, Guglielmo BJ. What is the clinical role of aerosolized ribavirin? DICP. 1990 Jul-Aug; 24(7-8):735-8. |
| Guglielmo BJ, Brooks GF. Antimicrobial therapy. Cost-benefit considerations. Drugs. 1989 Oct; 38(4):473-80. |
| Brodowy BA, Guglielmo BJ, York MK, Herfindal ET, Brooks GF. Experience with selective reporting of susceptibility to antimicrobial agents. Am J Hosp Pharm. 1989 Sep; 46(9):1816-8. |
| Tam J, Guglielmo BJ. Microbiology and antibiotics in infectious abdominal emergencies. Emerg Med Clin North Am. 1989 Aug; 7(3):611-29. |
| Guglielmo BJ, Schweigert BF, Kishi DT. Pharmacist-managed drug therapy in California hospitals. Am J Hosp Pharm. 1989 Jul; 46(7):1366-9. |
| Sue D, Salazar TA, Turley K, Guglielmo BJ. Effect of surgical blood loss and volume replacement on antibiotic pharmacokinetics. Ann Thorac Surg. 1989 Jun; 47(6):857-9. |
| Oliva SL, Guglielmo BJ, Jacobs R, Pons VG. Failure of intravenous vancomycin and intravenous metronidazole to prevent or treat antibiotic-associated pseudomembranous colitis. J Infect Dis. 1989 Jun; 159(6):1154-5. |
| Guglielmo BJ, Jacobs RA, Locksley RM. The exposure of health care workers to ribavirin aerosol. JAMA. 1989 Apr 07; 261(13):1880-1. |
| Guglielmo BJ, Salazar TA, Rodondi LC, Carver M, Goldstone J, Stoney RJ. Altered pharmacokinetics of antibiotics during vascular surgery. Am J Surg. 1989 Apr; 157(4):410-2. |
| Dugoni BM, Guglielmo BJ, Hollander H. Amphotericin B concentration in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis. Clin Pharm. 1989 Mar; 8(3):220-1. |
| Flaherty JF, Rodondi LC, Guglielmo BJ, Fleishaker JC, Townsend RJ, Gambertoglio JG. Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. Antimicrob Agents Chemother. 1988 Dec; 32(12):1825-9. |
| Guglielmo BJ, Rodondi LC. Comparison of antibiotic activities by using serum bactericidal activity over time. Antimicrob Agents Chemother. 1988 Oct; 32(10):1511-4. |
| Lam YW, Duroux MH, Gambertoglio JG, Barriere SL, Guglielmo BJ. Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers. Antimicrob Agents Chemother. 1988 Mar; 32(3):298-302. |
| R.J. Harrison, J. Bellows, D. Rempel, L. Rudolph, K. Kizer, A. Jin, B.J. Guglielmo. Assessing Exposures of Health-care Personnel to Aerosols of Ribavirin-California. Morbidity and Mortality Weekly Reports. 1988; 37:560-562. |
| B.J. Guglielmo and L.C. Rodondi. Comparison of Antibiotic Activity Using Serum Bactericidal Activity Over Time. Antimicrob. Agents Chemother. 1988; 32:1511-1514. |
| Y.W.F. Lam, M.H. Duroux, J.G. Gambertoglio, S.L. Barriere, and B.J. Guglielmo. Effect of Protein Binding on Serum Bactericidal Activities of Ceftazidime and Cefoperazone in Healthy Volunteers. Antimicrob. Agents Chemother9. Effect of Protein Binding on Serum Bactericidal Activities of Ceftazidime and Cefoperazone in Healthy Volunteers. 1988; 32:298-302. |
| P.A. Arnold, B.J. Guglielmo, and H. Hollander. Severe Hypersensitivity Reaction Upon Rechallenge With Trimethoprim-sulfamethoxazole in a Patient With AIDS. Drug Intell. Clin. Pharm. 22, 43-45 (1988). 1988; 22:43-45. |
| Arnold PA, Guglielmo BJ, Hollander H. Severe hypersensitivity reaction upon rechallenge with trimethoprim-sulfamethoxazole in a patient with AIDS. Drug Intell Clin Pharm. 1988 Jan; 22(1):43-5. |
| M.J. Mahlmeister, B.J. Guglielmo, and R. Harrison. We are Concerned About Ribavirin Exposure. Resp. Care. 1988; 33:809-810. |
| Guglielmo BJ, Flaherty JF, Woods TM, LaFollette G, Gambertoglio JG. Pharmacokinetics of cefoperazone and tobramycin alone and in combination. Antimicrob Agents Chemother. 1987 Feb; 31(2):264-6. |
| B.J. Guglielmo, J.F. Flaherty, T.M. Woods, G. LaFollette, and J.G. Gambertoglio. Pharmacokinetics of Cefoperazone and Tobramycin Alone and in Combination. Antimicrob. Ag. Chemother. 1987; 31:264-266. |
| Guglielmo BJ, Flaherty JF, Batman R, Barriere SL, Gambertoglio JG. Comparative pharmacokinetics of low- and high-dose ticarcillin. Antimicrob Agents Chemother. 1986 Sep; 30(3):359-60. |
| B.J. Guglielmo, J.F. Flaherty, R. Batman, S.L. Barriere, and J.G. Gambertoglio. Comparative Pharmacokinetics of Low- and High-Dose Ticarcillin. Antimicrob. Ag. Chemother. 1986; 30:359-360. |
| Glick PL, Guglielmo BJ, Tranbaugh RF, Turley K. Iodine toxicity in a patient treated by continuous povidone-iodine mediastinal irrigation. Ann Thorac Surg. 1985 May; 39(5):478-80. |
| P.L. Glick, B.J. Guglielmo, R.F. Tranbaugh, and K. Turley. Iodine Toxicity in a Patient Treated by Continuous Povidone-Iodine Mediastinal Irrigation. Ann. Thorac. Surg. 1985; 478-480(39). |
| Guglielmo BJ, Hohn DC, Koo PJ, Hunt TK, Sweet RL, Conte JE. Antibiotic prophylaxis in surgical procedures. A critical analysis of the literature. Arch Surg. 1983 Aug; 118(8):943-55. |
| Kehoe WA, Guglielmo BJ. Excessive potassium depletion with metolazone and furosemide. Clin Pharm. 1983 Jul-Aug; 2(4):304-5. |
| Quart BD, Guglielmo BJ. Prolonged diarrhea secondary to methyldopa therapy. Drug Intell Clin Pharm. 1983 Jun; 17(6):462. |
| B.J. Guglielmo, D.C. Hohn, P.J. Koo, T.K. Hunt, R.C. Sweet, and J.E. Conte. Antibiotic Prophylaxis in Surgical Procedures. A Critical Analysis of the Literature. Arch. Surg. 1983; 118:943-955. |
| W.A. Kehoe and B.J. Guglielmo. Excessive Potassium Depletion with Metolazone and Furosemide. Clin. Pharm. 1983; 2:304. |
| B.D. Quart and B.J. Guglielmo. Prolonged Diarrhea Secondary to Methyldopa Therapy. Drug Intell. Clin. Pharm. 1983; 17:462. |
| Brown KR, Guglielmo BJ, Pons VG, Jacobs RA. Theophylline elixir, moxalactam, and a disulfiram reaction. Ann Intern Med. 1982 Oct; 97(4):621-2. |
| K.R. Brown, B.J. Guglielmo, V.G. Pons, and R.A. Jacobs. Theophylline Elixir, Moxalactam, and a Disulfiram Reaction. Ann. Int. Med. 1982; 97:621-622. |